ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep
growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs
used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. It is not yet known whether chemotherapy is more effective with or without ZD
1839 for non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without ZD 1839 in treating patients who have stage IIIB or stage IV non-small cell
lung cancer.